GlaxoSmithKline (GSK) said that it is the first time the European Commission has approved a non-prescription product for weight loss.
The centrally approved marketing authorization means GSK can now introduce alli for adults with a body mass index of 28kg/m2 or more, in all 27 EU member countries. Plans are underway to launch alli in the coming months.
Manfred Scheske, president of GSK Consumer Healthcare Europe, said: “alli, in the US, has successfully helped millions of users lose weight gradually and steadily, and adopt a healthy lifestyle. We are very excited about the opportunity to create similar success in Europe and we will be launching alli in pharmacies throughout Europe soon.”